



POSTER PRESENTATION

Open Access

The toll-like receptor 4 agonist MRP8/14 protein complex (calprotectin) in autoinflammation: potential biomarker in chronic nonbacterial osteomyelitis – a case report

Juergen Brunner

From 21st European Pediatric Rheumatology (PReS) Congress
Belgrade, Serbia. 17-21 September 2014

Introduction

The cytoplasmic S100 proteins derived from cells of myeloid origin. Calprotectin (MRP8/14 protein complex) might be a biomarker either for autoinflammation and autoimmunopathy. Since autoinflammatory diseases might be a diagnostic challenge calprotectin may be helpful in the diagnosis of autoinflammatory diseases. Chronic non-bacterial osteomyelitis (CNO) is an autoinflammatory, noninfectious disease. CNO describes a wide spectrum from a monofocal bone lesion to the chronic recurring multifocal osteomyelitis (CRMO). Laboratory and histopathological findings are nonspecific. In some patients systemic inflammatory signs such as elevated acute phase proteins cannot be found.

Objectives

To test the ability of Calprotectin (MRP8/14 protein complex) serum concentrations to monitor disease activity in patients with CNO.

Methods

Serum concentrations of Calprotectin (MRP8/14 protein complex) in a patient with CNO were determined by a sandwich ELISA.

Results

Calprotectin (MRP8/14) level were raised heralding active disease when acute phase proteins (CrP, erythrocyte sedimentation rate). The calprotectin level was 7872,7 ng/ml (normal range 0-3000 ng/ml).

Conclusion

Calprotectin (MRP8/14) serum concentrations correlate closely with disease activity and may herald a flare before clinical manifestation. Therefore MRP8/14 serum concentrations are a biomarker indicating disease activity in CNO patients.

Disclosure of interest

None declared.

Published: 17 September 2014

doi:10.1186/1546-0096-12-S1-P255

Cite this article as: Brunner: The toll-like receptor 4 agonist MRP8/14 protein complex (calprotectin) in autoinflammation: potential biomarker in chronic nonbacterial osteomyelitis – a case report. *Pediatric Rheumatology* 2014 **12**(Suppl 1):P255.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

